I just added to my position in ELTP because the growth metrics are impressive and the revenue is expected to increase as they roll out more products. With a potential billion dollar market cap in two years, I see significant upside ahead.

I'm really convinced that $ELTP is set to grow significantly due to their strong market penetration strategy and upcoming drug launches. With a solid track record of profitability and expanding capacity, this company looks poised for substantial revenue growth in the near future.

Considering the significant increase in revenues and operating profits, along with the unusual short interest at a lower price, I believe Elite Pharmaceuticals is poised for growth. The large volume without much price movement suggests strong underlying interest and potential for a future rise in share price.

With multiple high-revenue generic medications pending launch and FDA approvals expected soon, I believe ELTP is poised for substantial profit and revenue growth. This positions them well for a potential move to NASDAQ or M&A activity, making it a promising swing trade opportunity.

As this stock gains more exposure with ongoing product approvals and FDA support, I believe ELTP will see significant growth. The potential risks are minimal and standard for the industry, making it a solid long-term investment with high upside potential.

Elite Pharmaceuticals has several key products slated for release and significant FDA approvals anticipated in the next few months. With strong revenue growth and a solid financial position, I believe ELTP is well-positioned for substantial gains, especially given the potential for M&A or a NASDAQ move.

With Elite Pharmaceuticals experiencing a 109% revenue surge in Q1 FY2025, I believe the stock is poised for a strong upward movement, making it a good opportunity for a swing trade.